SK BIOSCIENCE CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 58,800 KRW | +0.17% |
|
+2.26% | -18.33% |
| May. 03 | SK Bioscience's Attributable Loss Narrows in Q1 | MT |
| Mar. 28 | SK Bioscience Signs Deal with Sanofi for Five Vaccine Types | MT |
| Sales 2024 * | 248B 183M | Sales 2025 * | 325B 240M | Capitalization | 4,517B 3.33B |
|---|---|---|---|---|---|
| Net income 2024 * | -36B -26.57M | Net income 2025 * | -6B -4.43M | EV / Sales 2024 * | 17.4 x |
| Net cash position 2024 * | 194B 143M | Net cash position 2025 * | 667B 492M | EV / Sales 2025 * | 11.9 x |
| P/E ratio 2024 * |
-124
x | P/E ratio 2025 * |
-767
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 31.48% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.17% | ||
| 1 week | +2.26% | ||
| Current month | +0.34% | ||
| 1 month | -2.81% | ||
| 3 months | -9.12% | ||
| 6 months | -4.70% | ||
| Current year | -18.33% |
1 week
57 400.00
59 800.00
1 month
56 700.0060 700.00
Current year
56 700.0073 700.00
1 year
56 700.0088 600.00
3 years
56 700.00362 000.00
5 years
56 700.00362 000.00
10 years
56 700.00362 000.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jae-Yong An
CEO | Chief Executive Officer | 56 | - |
Yong-Sung Choi
DFI | Director of Finance/CFO | 51 | - |
Sally Choe
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jeffrey Choi
BRD | Director/Board Member | 60 | - |
Chang-Jin Moon
BRD | Director/Board Member | 71 | - |
Jae-Yong An
CEO | Chief Executive Officer | 56 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.57% | 2 M€ | -14.14% | ||
| 0.78% | 16 M€ | -4.51% | ||
| 0.04% | 15 M€ | +12.19% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 58,800 | +0.17% | 91,480 |
| 24-05-02 | 58,700 | +0.17% | 42,134 |
| 24-04-30 | 58,600 | -0.34% | 56,264 |
| 24-04-29 | 58,800 | +2.44% | 66,144 |
| 24-04-26 | 57,400 | -0.17% | 44,480 |
End-of-day quote Korea S.E., May 02, 2024
More quotes
SK Bioscience Co Ltd is a Korea-based company mainly engaged in the manufacture and sale of biological products. The Company's main products include vaccines such as SKYCellflu and Rotatech. The Company also sells infusion solutions. In addition, the Company engages in technology export business. The Company sells its products in domestic and overseas markets.
Sector
Pharmaceuticals
Calendar
2024-07-25
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
8
Last Close Price
58,800
KRW
Average target price
58,000
KRW
Spread / Average Target
-1.36%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -18.33% | 3.29B | |
| -3.79% | 87.06B | |
| +1.45% | 40.25B | |
| -15.94% | 31.09B | |
| +52.66% | 24.74B | |
| -14.50% | 15.91B | |
| -9.12% | 11.96B | |
| -14.38% | 11.92B | |
| -42.56% | 11.61B | |
| +4.87% | 8.73B |
- Stock Market
- Equities
- A302440 Stock
